Evidence map›Paper›PMID 39682105›Full record

ReviewCancers2024

The Rationale for Combining Hypofractionated Radiation and Hyperthermia.

Priyanshu M Sinha, Charlemagne A Folefac, Jens Overgaard, Michael R Horsman

Abstract readReview
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Priyanshu M SinhaExperimental Clinical Oncology-Department of Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark.ORCID 0000-0001-6115-1556
Charlemagne A FolefacExperimental Clinical Oncology-Department of Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark.
Jens OvergaardExperimental Clinical Oncology-Department of Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark.ORCID 0000-0002-0814-8179
Michael R HorsmanExperimental Clinical Oncology-Department of Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark.ORCID 0000-0003-1578-5691

Funding

European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 955625, Hyperboost 955625
6 · The paper itself

Abstract

The conventional radiation treatment of cancer patients has typically involved a large number of daily treatments with relatively low doses of radiation. However, improved technology has now resulted in the increased use of fewer radiation fractions at a high dose per fraction. This latter approach is often referred to as hypofractionated irradiation. While conventional radiation typically kills tumor cells through the production of DNA damage, treatments with higher doses per fraction have been suggested to also kill cells via the induction of vascular damage. Such vascular effects will also increase the level of adverse microenvironmental conditions, such as hypoxia and acidity, that already exist in tumors. Cells existing in these adverse microenvironmental conditions are resistant to radiation but actually sensitive to hyperthermia (heating at 40-45 °C) treatment. This suggests that the combination of hypofractionated radiation and heat may be a viable treatment approach. While there are preliminary pre-clinical and even clinical studies investigating this option, there are actually no data on the optimal application for the greatest therapeutic benefit. In this critical review, we will present the rationale for combining hypofractionated radiation with hyperthermia and discuss what has been done and what should be done to establish this combination as an effective cancer therapy option.

Indexed as

heathyperthermiahypofractionated radiationpre-clinical and clinical studiesstereotactic radiation

Identifiers

PMID39682105
PMCPMC11640455

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.